Given that CD99 has been recognized as a therapeutic target in disease stem cells in myeloid malignancies (Chung et al., 2017), it may be beneficial to explore clinical trials that target CD99 in ICC. The gene discussed is CD99; the disease is intrahepatic cholangiocarcinoma.